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Abstract
The QT interval, an electrocardiographic measure reflecting myocardial repolarization, is a 
heritable trait. QT prolongation is a risk factor for ventricular arrhythmias and sudden cardiac 
death (SCD) and could indicate the presence of the potentially lethal Mendelian Long QT 
Syndrome (LQTS). Using a genome-wide association and replication study in up to 100,000 
individuals we identified 35 common variant QT interval loci, that collectively explain ∼8-10% of 
QT variation and highlight the importance of calcium regulation in myocardial repolarization. 
Rare variant analysis of 6 novel QT loci in 298 unrelated LQTS probands identified coding 
variants not found in controls but of uncertain causality and therefore requiring validation. Several 
newly identified loci encode for proteins that physically interact with other recognized 
repolarization proteins. Our integration of common variant association, expression and orthogonal 
protein-protein interaction screens provides new insights into cardiac electrophysiology and 
identifies novel candidate genes for ventricular arrhythmias, LQTS,and SCD.
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Introduction
Prolongation or shortening of the QT interval on the electrocardiogram are non-invasive 
markers of delayed or accelerated myocardial repolarization, increased risk of sudden 
cardiac death (SCD) and fatal arrhythmia as a side effect of medication therapy. Mendelian 
Long and Short QT Syndromes (LQTS, SQTS)1 stem from mutations of strong effect (QT 
increase or decrease per mutation > ∼20-100 msec) in genes encoding ion channels or 
channel-interacting proteins. In unselected community-based individuals, variation in 
continuous QT interval is normally distributed (ranging from 380 to 460 msec), with 
heritability estimates of 30-40%2. Common genetic variants that are associated individually 
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with modest (≈1-4 msec/allele) increments in QT interval duration have been detected 
through candidate gene and genome-wide association studies (GWAS) in large sample sizes 
including the QTGEN3 and QTSCD4 consortia, as well as others5-9.
Several loci have been discovered independently in both genome-wide linkage studies of 
Mendelian LQTS families and GWAS of QT interval duration in unselected populations, 
including those harboring KCNQ1, KCNH2, SCN5A, KCNE1, and KCNJ2, highlighting the 
value of both approaches and the overlap of common and rare variant loci. To date, 
hundreds of rare mutations in 13 LQTS-susceptibility genes have been reported, with 75% 
of LQTS stemming from KCNQ1 (LQT1), KCNH2 (LQT2) and SCN5A (LQT3) mutations, 
< 5% due to LQT4-13 and ∼20% remaining genetically elusive. Identification of the causal 
genes underlying QT interval variation in the general population has been more challenging.
Here, the QT Interval-International GWAS Consortium (QT-IGC) performed an expanded 
meta-analysis of GWAS in 76,061 individuals of European ancestry with targeted 
genotyping in up to 33,316 additional individuals, completed mutational analysis in 
probands with genetically elusive LQTS, determined whether QT-associated SNPs have 
effects on gene expression in various tissues (eQTLs) or on other human phenotypes, and 
further annotated QT-associated genes using protein-protein interaction analyses.
GWAS identifies 22 novel QT loci
Clinical characteristics of 31 study cohorts of European ancestry who contributed to the 
stage 1 GWAS are shown in Supplementary Table 1. All studies excluded individuals with 
atrial fibrillation, QRS duration greater than 120 msec, bundle branch block, or 
intraventricular conduction delay, and when available electronic pacemaker use or QT-
altering medication use. In each cohort, QT interval duration adjusted for age, sex, RR 
interval (inverse heart rate), and principal components of genetic ancestry was tested for 
association with 2.5 million directly genotyped or imputed SNPs under an additive genetic 
model (Supplementary Table 2 and 3). We performed inverse variance weighted meta-
analysis on the GWAS results from 76,061 individuals, and observed only modest over-
dispersion of the test statistics given the sample size (λGC = 1.076, Supplementary Figure 
1a). Exclusion of SNPs within 500kb of the sentinel SNP at genome-wide significant loci 
(some identified only after incorporation of replication genotyping; see below) did not 
significantly attenuate the excess of low p-values, consistent with a polygenic model of QT 
interval variation10 (λGC = 1.069, Supplementary Figure 1b).
At an interim meta-analysis of GWAS results, SNPs were selected for two forms of 
replication. First, a set of the top 35 independent SNPs (one per locus) were selected for 
targeted replication genotyping in as many as 31,962 individuals of European ancestry 
(Supplementary Table 1) on a variety of platforms (Supplementary Table 2). Second, a set 
of ∼5,000 LD-pruned (r2 > 0.2) SNPs with nominal evidence of association with QT 
interval (P ≤ 0.015) were included in a custom genotyping array (Metabochip) and 
genotyped in 1,354 individuals (Supplementary Note, Supplementary Tables 1, 4, 5)11. 
Meta-analysis of all GWAS and replication genotyping results in up to 103,331 individuals 
(Supplementary Note) identified a total of 35 genome-wide significant (P < 5×10-8) loci, of 
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which 22 were novel and 13 have been reported previously3-5,9 (Table 1, Figure 1, 
Supplementary Table 6). Some SNPs initially selected for replication genotyping were not 
ultimately the most significant SNP at a locus (Supplementary Table 7). Many loci had 
evidence of multiple independent signals of association based on having low LD (r2 < 0.05) 
to other genome-wide significant SNPs, with a total of 68 independent SNPs at 35 loci 
(Supplementary Note, Supplementary Table 8a, Supplementary Figure 2).
Association of QT SNPs in individuals of African Ancestry
We examined the association of 67 of these SNPs in 13,105 individuals of African ancestry 
in the CARe-COGENT consortium12 (one SNP was poorly imputed due to low minor allele 
frequency, MAF). Despite the limited power due to smaller sample size, 10 SNPs at 9 loci 
were significantly associated with QT interval (P < 0.0007 = 0.05/67) in the same direction 
as in QT-IGC (Supplementary Table 9). The SNP direction of effect was concordant 
between European- and African-derived samples for 51/67 SNPs (binomial P = 5×10-5) and 
effects were highly correlated (r = 0.60, P = 9×10-10, Supplementary Table 9). These 
findings are consistent with the hypothesis that a majority of common variants are associated 
with QT interval in both ancestral populations.
Variants with additional non-QT effects
Because heart rate (HR) is a strong determinant of unadjusted QT interval (r2 ∼0.5-0.8), we 
examined the 68 independent SNPs at 35 QT loci in a HR GWAS in 92,355 individuals of 
European or Indian Asian ancestry13. Among the 35 loci examined, we found significant 
association with HR of 5 SNPs at the 4 loci including PLN, FEN1—FADS2, ATP2A2, and 
SCN5A-SCN10A (p < 0.0007 = 0.05/68, Supplementary Table 10). Arguing against 
inadequate heart rate adjustment as the source of association of QT variants with HR was the 
modest correlation of QT effects (in models adjusting for RR interval, inverse heart rate) and 
HR effects for QT associated SNPs (r2 = 0.16). Only 38 of 68 of the SNP effects on HR 
showed the inverse relationship that has been well established between QT interval duration 
and HR (binomial p = 0.20).In ARIC (n = 8,524), we found no evidence that QT-SNP 
associations were altered with additional adjustment for RR2, RR3, RR1/2 or RR1/3. In total, 
these findings favor independent pleiotropic effects of the SNPs on heart rate and QT 
interval.
QRS prolongation due to bundle branch block can result in delayed myocardial 
repolarization and QT prolongation, hence our exclusion of individuals with prolonged QRS 
duration/bundle branch block (Supplementary Note). We examined QT interval SNPs in a 
published GWAS of QRS duration (N = 40,407), which reflects electrical impulse 
propagation in the cardiac ventricles14. Among the 68 QT-associated SNPs, 15 were 
significantly associated with QRS duration (p < 0.0007) at 8 loci (Supplementary Table 
10)7,14.Because QRS duration is a subinterval of QT interval on the ECG, it is perhaps not 
surprising that some QT-prolonging variants are also positively associated with QRS 
duration. However, the significant genetic effects show concordant (N = 6) as well as 
discordant effects (N = 9).Across all SNPs there was no significant excess of concordant vs 
discordant effects (37 vs 31, binomial p = 0.27) or significant correlation of effect sizes (r2 = 
Arking et al. Page 3
Nat Genet. Author manuscript; available in PMC 2015 February 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
0.03, p = 0.18, Supplementary Table 10). Collectively, these findings suggest that while the 
fundamental electrophysiologic mechanisms underlying the SNP-QT relationships for some 
SNPs may be shared, many involve cell-type-specific effects and that a consistent general 
relationship between SNP effects on QT interval and QRS duration does not hold.
Examination of the NHGRI GWAS database (Supplementary Note) revealed additional 
associations of our QT associated SNPs (or their close proxies with r2 > 0.8) at SCN5A-
SCN10A with PR interval15, at MKL2 with age of menarche16 and at FEN1-FADS2 with 
high-density lipoprotein cholesterol, triglycerides17, n-3 fatty acids18, fasting plasma 
glucose and HOMA-B19 and alkaline phosphatase20 (Supplementary Table 11), which may 
point to novel repolarization mechanisms or simply reflect independent (pleiotropic) effects 
of the same genetic variation in different tissues.
Functional annotation of associated variants
Because common variants that code for changes in protein structure have an increased 
potential to be causal, we investigated the presence of coding variants among QT-associated 
loci using 1000 Genomes Project data (CEU).Among 68 total genome-wide significant 
SNPs at 35 loci, there were 5 loci in which the index or a highly correlated SNP was 
nonsynonymous.(Supplementary Table 8b).While most loci have multiple genes in 
associated intervals (Supplementary Figure 2), the genes that harbor genome-wide 
significant missense SNPs highly correlated with the top SNP are high-priority candidates to 
underlie the QT interval association at those loci.
Since non-coding variants may influence gene expression, we examined the index SNPs or 
proxies (r2 > 0.8) at the 68 SNPs at 35 loci in publicly available eQTL datasets from diverse 
tissues. Twelve QT interval loci are associated with variable expression of at least one gene 
in one or more tissues with high correlation (r2 > 0.8) between the top QT SNP and the top 
eQTL SNP (Supplementary Note, Table 1, Supplementary Table 12). QT-associated SNPs 
are associated with expression of the nearest gene at loci including ANKRD9, ATP1B1, 
CNOT1, FADS1, LIG3, and TCEA3. The eQTL data help point to specific genes at these loci 
as a potential source of the repolarization association signal, presumably through regulatory 
variation. However, some loci are associated with expression of multiple genes. We did not 
observe a significant signature of eQTLs among the QT loci that implicate a specific tissue 
or cell type in an atlas of human and mouse expression (P>0.01, Supplementary Note)21.
Because genetic variants that influence gene expression may do so in a cell-type specific 
manner, we examined the association of QT-associated SNPs with gene expression in a 
collection of 313 left ventricular biopsy samples in the MAGNet consortium. This collection 
included samples from the hearts of individuals transplanted for heart failure (n=177) or 
healthy hearts from potential donors (n=136) that were ultimately not used (Supplementary 
Note). We examined 63 of the 68 QT-associated SNPs that were well imputed from 
genome-wide genotyping in relation to cis-expression of all genes within 1Mb of each SNP.
After adjusting for age, sex, study site and presence of heart failure, 9 SNPs at 8 loci were 
significantly associated with one of 9 transcripts (one SNP was associated with 2 
transcripts), correcting for multiple testing (P < 4.4 × 10-5 = 0.05/1,146 SNP-transcript 
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associations, Supplementary Note, Table 2). After adjustment for the best eSNP, the QT 
SNP association became non-significant (all P ≥ 0.01) for 8 of the 9 SNP-transcript 
associations, consistent with a potentially causal effect for these 8 eQTLs. Inclusion of 
interaction terms for heart failure status did not alter the results (data not shown). In sum, 
these findings highlight several genes that are plausibly modulated by the QT SNP (or a 
correlated variant) and thus high priority targets for further experimental work.
Lastly, because genetic variation that influences gene expression may act through 
modulation of enhancers, we examined data available from the NIH Roadmap Epigenomics 
Program22. We specifically focused on transcriptional enhancer elements marked by 
combinations of histone modifications (specifically presence of H3K4me1 and absence of 
H3K4me3), as emerging evidence indicates that variants associated with complex traits 
preferentially reside in these non-coding regulatory regions and can affect gene 
expression23,24. We tested whether lead QT interval-associated SNPs or highly correlated 
variants (r2>0.8) overlapped enhancers in adult left ventricular tissue. Of 68 lead (or 
correlated) SNPs, 34 overlapped a left ventricular enhancer, a substantially greater 
proportion than randomly sampled sets of matched SNPs (z-score = 9.45, P ≪ 10-200 
Supplementary Note, Supplementary Figure 3). These findings highlight specific SNPs at 
QT-associated loci that can be prioritized for experimental follow-up (Supplementary Table 
13).
We also examined the association results for over-representation of specific pathways in QT 
loci compared to the genome as a whole using GO, KEGG, Panther, and Ingenuity gene set 
annotations (Supplementary Note). Three of the top 10 pathways in this analysis are 
specifically involved in calcium processes including: “regulation of the force of heart 
contraction” (P = 1×10-4), “cation transport” (5x10-4), “cellular calcium ion homeostasis” 
(1×10-3, Supplementary Note, Supplementary Table 14)25. These signals were confirmed by 
a secondary analysis, in which we matched the 68 QT-associated SNPs to randomly selected 
genome-wide SNPs to calculate statistical significance (Supplementary Note). Three GO 
terms involving “ion transport” were significantly enriched for QT associations (P < 
0.00044) as well as a gene set based on having a cardiac phenotype in knockout mice (P < 
0.00025, Supplementary Note).
Population variation in QT interval explained
The common variants at the 12 previously published common variant loci from the QTGEN 
and QTSCD consortia explained 3-6% of variation in QT interval, after accounting for 
effects of age, sex and heart rate3,4. The top SNPs at the additional novel loci increase the 
variance explained to 5.5-7.0%, while all 68 independent SNPs at the 35 loci explain 
7.6-9.9% of variance (Supplementary Tables 15 and 16). A recent heritability analysis found 
that 21% of overall variance (>50% of heritable variation) in QT interval is explained by 
common autosomal SNPs captured on contemporary genome-wide genotyping arrays10. 
Because the current study was focused on identifying bona fide associations of specific loci, 
rather than explaining overall variance, we set a stringent p-value threshold for identifying 
individual SNPs. Larger studies are likely to continue to identify additional novel QT loci, 
as well as additional independent signals of association at the 35 loci described here.
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LQTS proband mutation screening
Common variant loci found in the current and prior studies include 5 genes previously 
established to cause monogenic LQTS (KCNQ1, KCNH2, SCN5A, KCNE1, and KCNJ2). 
Given the co-existence of common QT variants at loci with established rare coding 
mutations in LQTS disease genes, we hypothesized that some of the novel QT loci may 
likewise contain previously unrecognized Mendelian LQTS genes. We selected on the basis 
of statistical significance, proximity to the signal of association, absence of multiple nearby 
genes in the associated interval and known cardiac expression or involvement in ion flux, 6 
genes (ATP2A2, CAV1, CAV2, SLC8A1, SRL, and TRPM7) from 5 novel loci for coding 
mutation screening. We studied 298 unrelated individuals with clinically diagnosed LQTS 
on the basis of the Schwartz score, but genotype negative for the canonical LQTS1-3 
causative genes, for rare exonic or splice site sequence variants in these 6 genes 
(Supplementary Note, Supplementary Table 17). We identified 13 amino acid-altering 
variants present in cases but not in ≥ 300 controls of the same continental ancestry (Table 3). 
Of these, 11 were not observed in ∼6,800 individuals whole-exome sequenced by the 
Exome Sequencing Project (ESP), or included on the Exome Chip array; several are 
predicted to be disruptive to protein function (Supplementary Note, Table 3).
Of the 13 amino-acid altering variants, two mutations in ATP2A2 (p.Ile276fsX281) and 
TRPM7 (p.Ile19fsX59) result in frame shifts and premature truncation of the corresponding 
protein product. The ATP2A2 mutation was detected in a 6-year old girl with LQTS on the 
basis of a QTc of 492 msec without symptoms. The proband's mother carried the mutant 
allele and had borderline QTc prolongation and T wave abnormalities; the proband's father 
lacked the mutation and had a normal QTc. The TRPM7 mutation was detected in a 14-year 
old girl with LQTS on the basis of a QTc of 500 msec without symptoms. The mutation was 
found in the proband's mother and brother, both of whom had a normal QTc, and was absent 
in the proband's father who had a normal QTc. Whether or not these two loss-of-function 
alleles contribute to LQTS pathogenesis in these individuals cannot be determined from 
these observations alone.
Protein-protein interaction networks
We next sought evidence that proteins encoded by genes at common variant loci interact 
physically with known myocardial repolarization proteins. We have constructed a protein-
protein interaction network from the InWeb database (Supplementary Note)26. Using the 
DAPPLE algorithm27 we seeded the network with the first 12 known Mendelian LQTS 
genes and seven loci harboring previously-identified common QT variants (but not known 
Mendelian genes)3,4. Consistent with the known relationships among several of the 
Mendelian genes, significant interconnectivity was observed (P = 0.0006 for direct 
connections, P = 0.008 for indirect connections, Supplementary Note). We thus identified 
606 proteins interacting directly with the seed proteins and investigated whether these 
protein-protein interactions could help identify candidate genes within any of the 22 novel 
loci identified in the current study. We found 8 interactors from 7 novel loci (ATP2A2, 
CAV1, CAV2, PRKCA, SLC8A1, ATXN1, ETF1, SGOL2), representing significant 
enrichment compared to the null expectation (hypergeometric P = 0.03, Supplementary 
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Note, Supplementary Table 18). We hypothesized that the other proteins interacting directly 
with the seed network may nonetheless be enriched for association, even if not genome-wide 
significant. We assigned association scores to all interacting proteins (except those in the 35 
loci already identified) and tested for enrichment of association in those genes compared to 
all genes in the genome from non-associated regions. We found that interacting proteins 
were more associated than chance expectation (rank-sum P = 0.00012), suggesting that they 
include true associations yet to be discovered (Supplementary Figure 4, Supplementary 
Note). The protein interaction network analysis suggests that interactors of Mendelian LQTS 
genes are functionally involved in QT interval duration.
This conclusion is further supported by in vivo data presented in an accompanying paper by 
Lundby et al. (in press, Nature Methods). We immunoprecipitated proteins encoded by the 
Mendelian LQTS genes, KCNQ1, KCNH2, CACNA1C, CAV3 and SNTA1 from murine 
cardiac tissue and identified proteins they interact with by high performance orbitrap tandem 
mass spectrometry. We found proteins encoded by 12 genes from 10 loci identified by our 
GWAS that physically interact with proteins encoded by the 5 Mendelian LQTS genes, a 
significant enrichment compared to random expectation (P = 1×10-6 using permutation), 
including ATP2A2 (SERCA2a), SRL (sarcalumenin), which regulates SERCA2a in 
cardiomyocytes28-30, CAV1 (caveolin 1), PLN (phospholamban), which also regulates 
SERCA2a, and ATP1B1 (Table 1). Molecular interactions of proteins encoded by genes at 
QT-associated loci with known mediators of the currents underlying myocardial 
repolarization strongly implicates these genes, and not others in the relevant associated 
intervals, as the causal genes underlying the QT interval association.
Discussion
Altogether, our integrated analysis of genomic, transcriptomic and proteomic data highlight 
calcium signaling as playing an important role in myocardial repolarization, the cellular 
process that underlies the QT interval, derangement of which is arrhythmogenic (see 
detailed description of genes at several loci in Supplementary Note).
Electrical activation and relaxation of the ventricular myocyte on average once per second 
requires the interplay of multiple coordinated ion channel fluxes. Cellular depolarization 
begins with Na+ influx and is sustained by Ca2+ influx, which triggers Ca2+ release from the 
sarcoplasmic reticulum leading to myocardial contraction (Supplementary Figure 5). 
Prolonged inward (depolarizing) Ca2+ current during the plateau phase of the cardiac action 
potential leads to delays in ventricular myocyte repolarization, a subsequent prolonged QT 
interval on electrocardiogram, and a highly arrhythmogenic and potentially lethal substrate. 
In fact, gain-of-function mutations in the L-type Ca2+ channel lead to the highly 
arrhythmogenic Timothy syndrome (LQT8) that is associated with extremely prolonged QT 
intervals31.
Normal myocyte repolarization results from efflux of potassium and less so Ca2+; Ca2+ is 
actively taken up by the sarcoplasmic reticulum to halt myocardial contraction. The Na+ that 
enters the myocyte is counterbalanced by an active Na+/K+ ATPase (a beta subunit of which 
is encoded by ATP1B1, at a common variant QT locus). The Ca2+ that enters the myocyte is 
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counterbalanced by a Na+/Ca2+ exchanger (NCX1, encoded by SLC8A1) to ensure net even 
cation balance, at the expense of a net depolarizing effect (potentially prolonging 
repolarization). Disruption of this delicate cation balance, and in particular Ca2+ 
homeostasis, can have a profound impact on action potential duration, formation of early 
afterdepolarizations (EADs), and triggered activity, leading to potentially lethal arrhythmias 
including torsade de pointes and ventricular fibrillation. In fact, administration of an 
inhibitor of the Na+/Ca2+ exchanger is associated with reduced arrhythmia and shortened 
action potential duration in models of LQTS32 and heart failure33 and its over-expression 
delays myocardial repolarization and leads to ventricular arrhythmias34.
ATP2A2 encodes the SERCA2a cardiac sarcoplasmic reticulum calcium pump and by 
alternative splicing a ubiquitously expressed SERCA2b calcium pump (Supplementary 
Figure 5). The protein is negatively regulated by phospholamban (PLN), also a QT-interval 
associated locus3,4,6. In turn, PLN is negatively regulated by PRKCA, a gene in a newly 
discovered QT-interval associated locus35. SERCA2a is responsible for Ca2+ sequestration 
by the cardiac sarcoplasmic reticulum and its dysregulation is implicated in heart failure due 
to the centrality of calcium cycling to excitation-contraction coupling. Dominant SERCA2 
mutations are a cause of keratosis follicularis Darier-White disease (OMIM #124200)36. No 
study that we are aware of has described electrocardiographic or other cardiac changes in 
affected humans but detailed investigation of heterozygous Serca2 (+/-) mice show a 
reduction in Serca2 protein by about a third with deficits in myocardial relaxation and 
contractility, and a reduced Ca2+ transient by haploinsufficiency37 as well as upregulation of 
transient receptor potential canonical 1 (TRPC1) channel38. Moreover, overexpression of 
SERCA2a in a rat model of heart failure demonstrated a substantial reduction in 
arrhythmias39.
TRPM7 encodes the widely expressed transient receptor channel melastatin 7 protein, a 6 
transmembrane molecule which is Mg2+ and Ca2+ permeable and has protein kinase 
function40,41. The touchtone/nutria zebrafish TRPM7 mutant demonstrates defective 
skeletogenesis, kidney stones42 and abnormal melanophores43. Trpm7 (-/-) deletion in mice 
is embryonic lethal; targeted deletion disrupts normal thymogenesis40. Targeted cardiac 
deletion in cultured embryonic ventricular myocytes leads to down-regulation of several 
genes involved in calcium cycling, including SERCA2a44. In migrating human embryonic 
lung fibroblasts, TRPM7 mediates transduction of mechanical stretch into calcium influx 
underlying calcium flickers (focally high intracellular calcium microdomains), involved in 
steering cell migration45. In human atrial fibroblasts, atrial fibrillation is associated with 
increased TRPM7-mediated Ca2+ influx while TRPM7 knockdown results in loss of 
spontaneous Ca2+ influx46. More recently, targeted Trpm7 deletion in mice has been shown 
to result in lethal cardiomyopathy in early cardiogenesis; cardiomyopathy, delayed 
repolarization and heart block in mid cardiogenesis; and no recognizable phenotype in late 
cardiogenesis47. In total, this prior work raises the possibility that TRPM7 in humans leads 
to altered myocardial repolarization through developmental differences or through ongoing 
functional effects in adulthood, potentially involving calcium signaling.
Potassium flux has long been recognized through rare mutations underlying LQTS as a 
critical effector of myocardial repolarization. Ca2+ has been recognized as a central mediator 
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in excitation-contraction coupling. However, our studies of common and rare genetic 
variation now place Ca2+ as a central modulator of repolarization given the role of the 
proteins encoded by the Mendelian Timothy syndrome gene (LQT8) CACNA1C, as well as 
the following genes at common variant QT interval loci: ATP2A2, PLN, PRKCA and SRL 
and SLC8A1. How the Mg2+/Ca2+ channel TRPM7 might contribute to repolarization is 
unclear but its involvement in Ca2+ flickers45 suggests a potential role in localized Ca2+ 
fluxes or indirect effects on Ca2+-sensitive potassium channels or the Na+/Ca2+ exchanger.
Much work will be needed to understand the normal physiologic contribution to 
repolarization of these Ca2+-regulating proteins, as well as the pathophysiologic 
consequences arising from their derangements. While anti-arrhythmic agents targeting the 
IKr (LQT2/KCNH2) channel have a relatively limited contribution to clinical management of 
some arrhythmias due to their propensity to cause other arrhythmias, targeting the newly 
identified proteins that contribute to myocardial repolarization could potentially treat some 
arrhythmias without pro-arrhythmia. Conversely, existing therapies that inadvertently target 
some of the newly discovered proteins could in fact contribute to arrhythmogenesis.
We have identified 22 novel QT interval loci, bringing to a total 35 common variant loci. 
We have used diverse approaches to highlight specific genes at these loci likely to mediate 
the repolarization effects. While we cannot say with certainty which gene underlies the QT 
trait at every locus, these complementary experiments represent a quantum leap in our 
understanding of this critical electrophysiologic process. The elucidation of fundamental 
mechanisms of arrhythmogenesis promises to expose new approaches to predict and prevent 
death from lethal ventricular arrhythmias in the general population.
Online Methods
Study cohorts
Cohorts for QT interval association analyses included individuals largely with population- or 
community-based ascertainment and a few with case-control sampling for traits not strongly 
associated with QT interval. Mandatory exclusions included presence of atrial fibrillation or 
a trial flutter, and presence of QRS duration > 120 msec or presence of right or left bundle 
branch block. Optional exclusions included use of QT-altering medications, presence of a 
pacemaker or implantable cardioverter defibrillator, or pregnancy. All studies were reviewed 
by local ethics committees and all participants provided informed consent.
Genotyping, imputation, quality control
GWAS studies used a variety of genome-wide genotyping arrays. All studies used hidden 
Markov model approaches to impute genotypes at unmeasured HapMap SNPs so that a 
common set of 2.5M SNPs were available across all discovery samples. Monomorphic SNPs 
and SNPs with beta estimates larger than 100,000 were removed from all results. Cohort-
specific SNP filters on minimum minor allele frequency, imputation quality metric, call rate 
and Hardy-Weinberg equilibrium p-value were selected to minimize any test statistic 
distortion of the quantile-quantile plot or genomic inflation factor (λ). Replication 
genotyping was performed using a variety of arrays.
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Association analyses, meta-analysis
Genomic control was applied to genome-wide results from each cohort prior to meta-
analysis. Meta-analyses were performed in parallel at two analytic sites using MANTEL3 or 
METAL48 using inverse variance weighted, fixed effects meta-analysis. Genome-wide 
significance was set at P < 5×10-8, a threshold accounting for the effective number of 
independent common variant tests in the genome of European-derived populations.49
Expression in cardiac samples
Samples of cardiac tissue were acquired from patients in the Myocardial Applied Genomics 
Network. Left ventricular free-wall tissue was harvested at the time of cardiac surgery from 
subjects with heart failure undergoing transplantation or from unused donor hearts. DNA 
samples were genotyped using the Affymetrix 6.0 genome-wide array and RNA expression 
measured using the Affymetrix Genechip ST1.2 array. Imputation to SNP genotypes in 1000 
Genomes was performed. Analyses were restricted to samples with genetically inferred 
European ancestry. SNP genotype was tested for association with log2 transformed 
expression level, after adjustment for age, sex, study site, disease status and batch. 
Association of each QT-associated SNP with all transcripts within 1Mb of the SNP was 
examined for 63 QT-associated SNPs (5 SNPs were not available due to poor imputation). 
SNP-transcript associations meeting experiment-wide significance (P < 4.4×10-5 = 
0.05/1,146 tests) were examined after additional adjustment for the best cis eSNP for the 
transcript in question. We inferred that the SNP-transcript association could explain the 
SNP-QT association when the SNP-QT association was substantially attenuated after 
additional adjustment for the best cis eSNP.
Cardiac enhancer analyses
Enhancer annotations were generated by integrating combinations of histone modifications 
obtained from the Roadmap Epigenomics project using ChromHMM23,50. We identified 
SNPs in LD (r2> 0.8) with each of the 68 QT interval-associated loci using genotype data 
from the 1000 Genomes Project (CEU population) and computed overlap with 
ChromHMM-annotated enhancer elements in the left ventricle tissue sample (BC Left 
Ventricle N41) in the NIH Roadmap Epigenomics Program22 using the intersect BED 
command in BED Tools (v2.12.0). To assess significance of the overlap, we compared the 
set of SNPs at 68 QT interval-associated loci against 100,000 sets of randomly sampled 
control SNPs. Control SNPs were chosen from the Affymetrix 660W genotyping array and 
were matched for size of the LD block (+/- 5 SNPs), MAF of the lead SNP (+/- 0.1) and 
distance to the nearest gene (+/- 25 kb if outside a gene).
LQTS mutation analysis
A cohort of 298 unrelated, LQT1-3 mutation negative patients with LQTS [191 females 
(64%), average age= 27 ± 20 years, average QTc = 529 ± 58 ms], who satisfied the case 
inclusion criteria of QTc ≥ 480 msec (n= 261, 86%) or Schwartz score51 ≥3.0 (n=298, 
100%), was derived from 7 international congenital LQTS recruitment centers [l'Institut du 
Thorax, Nantes, France (n=91), Mayo Clinic, Rochester, Minnesota, United States (n=72), 
University of Pavia, Pavia, Italy (n=38), Academic Medical Centre, Amsterdam, 
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Netherlands (n=30), The Hospital for Sick Children, Toronto, Ontario, Canada (n=24), 
Munich Medical International GmbH, München, Germany (n=23), and St. George's 
Hospital, London, England (n=20)]. Of the 265 patients with a documented clinical history, 
175 (66%) were symptomatic with ≥ 1 LQTS-related cardiac event (i.e. syncope or cardiac 
arrest). Six genes (ATP2A2, CAV1, CAV2, SLC8A1, SRL, TRPM7), derived from 5 genome-
wide significant novel loci, were selected for comprehensive open-reading frame/splice-site 
mutation analysis. These 6 candidate genes were chosen based on nominal statistical 
significance, proximity to the signal of association, absence of multiple nearby genes in the 
associated interval, and known cardiac expression or involvement in ion channel 
macromolecular complexes. For each gene, mutational analysis was performed using either 
direct Sanger-based DNA sequencing of all patient samples or using an intermediate 
mutation detection platform (i.e. denaturing high performance liquid chromatography 
[DHPLC]) followed by direct DNA sequencing of only samples showing an aberrant 
DHPLC elution profile.
Protein-protein interaction in silico analyses
We used a public database of protein-protein interactions26. This database contains 428,430 
interactions, 169,810 of which are high-confidence interactions across 12,793 proteins. All 
human interactions were pooled and interactions in orthologous protein pairs passing a strict 
threshold for orthology were included. Each interaction was assigned a probabilistic score 
based on the neighborhood of the interaction, the scale of the experiment in which the 
interaction was reported and the number of different publications in which the interaction 
had been sited. We used a published algorithm called DAPPLE (Disease Association 
Protein-Protein Link Evaluator) to build and analyze a network of seed genes27. We seeded 
the network with 12 known Mendelian LQTS proteins (KCNQ1, KCNH2, SCN5A, KCNE1, 
KCNE2, CAV3, SNTA1, KCNJ2, CACNA1C, ANK2, AKAP9, SCN4B) as well as genes 
from 7 previously associated common variant QT loci3,4. We considered direct connections 
among the seed proteins as well as indirect connections through other proteins, filtering on 
connections between proteins from different loci. DAPPLE evaluates the significance of the 
network and individual proteins within it by comparing it to 10,000 random, matched 
networks that are generated using a within-degree node-label permutation27. We considered 
the ability of protein-protein interactions to identify proteins newly associated in the QT-
IGC meta-analysis. We translated the novel loci into genes, identifying 124 genes in total, 
85 of which were in the In Web database.
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Refer to Web version on PubMed Central for supplementary material.
Authors 
Dan E. Arking1,*, Sara L. Pulit2,3,4,*, Lia Crotti5,6,7, Pim van der Harst8,9, Patricia B. 
Munroe10,11, Tamara T. Koopmann12, Nona Sotoodehnia13,14, Elizabeth J. 
Rossin3,15,16, Michael Morley17, Xinchen Wang18,19,20, Andrew D. Johnson21, Alicia 
Lundby3,22,23, Daníel F. Gudbjartsson24, Peter A. Noseworthy2,3,25, Mark 
Eijgelsheim26, Yuki Bradford27, Kirill V. Tarasov28, Marcus Dörr29,30, Martina 
Arking et al. Page 11
Nat Genet. Author manuscript; available in PMC 2015 February 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Müller-Nurasyid31,32,33,34,35, Annukka M. Lahtinen36,37, Ilja M. Nolte38, Albert 
Vernon Smith39,40, Joshua C. Bis13, Aaron Isaacs41, Stephen J. Newhouse10, 
Daniel S. Evans42, Wendy S. Post43,44, Daryl Waggott45, Leo-Pekka Lyytikäinen46, 
Andrew A. Hicks47, Lewin Eisele48, David Ellinghaus49, Caroline Hayward50, Pau 
Navarro50, Sheila Ulivi51, Toshiko Tanaka52, David J. Tester53,54, Stéphanie 
Chatel55,56, Stefan Gustafsson57,58, Meena Kumari59, Richard W. Morris60, Åsa T. 
Naluai61,62, Sandosh Padmanabhan63, Alexander Kluttig64, Bernhard Strohmer65, 
Andrie G. Panayiotou66,67, Maria Torres68, Michael Knoflach69, Jaroslav A. 
Hubacek70, Kamil Slowikowski71,72, Soumya Raychaudhuri3,71,73,74,75, Runjun D. 
Kumar76,77, Tamara B. Harris78, Lenore J. Launer78, Alan R. Shuldiner79,80,81, 
Alvaro Alonso82, Joel S. Bader83, Georg Ehret1, Hailiang Huang3,15,16, W.H. Linda 
Kao44, James B. Strait28,52, Peter W. Macfarlane84, Morris Brown85, Mark J. 
Caulfield10, Nilesh J. Samani86, Florian Kronenberg87, Johann Willeit69, CARe 
Consortium88, COGENT Consortium88, J. Gustav Smith2,3,25,89, Karin H. 
Greiser64,90, Henriette Meyer zu Schwabedissen91, Karl Werdan92, Massimo 
Carella93, Leopoldo Zelante93, Susan R. Heckbert13,94, Bruce M. Psaty13,94,95,96,97, 
Jerome I. Rotter98, Ivana Kolcic99, Ozren Polašek99, Alan F. Wright50, Maura 
Griffin100, Mark J. Daly3,15, DCCT/EDIC88, David O. Arnar101, Hilma Hólm24, Unnur 
Thorsteinsdottir24, eMERGE consortium88, Joshua C. Denny102,103, Dan M. 
Roden103,104,105, Rebecca L. Zuvich27, Valur Emilsson39, Andrew S. Plump106, 
Martin G. Larson21,107,108, Christopher J. O'Donnell21,109, Xiaoyan Yin21,107, Marco 
Bobbo110, Adamo P. D'Adamo51,111, Annamaria Iorio110, Gianfranco Sinagra110, 
Angel Carracedo68,112,113, Steven R. Cummings42, Michael A. Nalls114, Antti 
Jula115, Kimmo K. Kontula116, Annukka Marjamaa36,37, Lasse Oikarinen117, Markus 
Perola118,119,120, Kimmo Porthan117, Raimund Erbel121, Per 
Hoffmann122,123,124,125, Karl-Heinz Jöckel48, Hagen Kälsch121, Markus M. 
Nöthen122,123, HRGEN consortium88, Marcel den Hoed58,126, Ruth J.F. 
Loos126,127,128, Dag S. Thelle129,130, Christian Gieger33, Thomas 
Meitinger35,131,132, Siegfried Perz133, Annette Peters35,134, Hanna Prucha135,136, 
Moritz F. Sinner31, Melanie Waldenberger132, Rudolf A. de Boer8, Lude Franke9, 
Pieter A. van der Vleuten8,9, Britt Maria Beckmann31, Eimo Martens31,137, 
Abdennasser Bardai12, Nynke Hofman138, Arthur A.M. Wilde12,139, Elijah R. 
Behr140, Chrysoula Dalageorgou141, John R. Giudicessi54, Argelia Medeiros-
Domingo54, Julien Barc56, Florence Kyndt55,56, Vincent Probst55,56, Alice 
Ghidoni5,6, Roberto Insolia5,6, Robert M. Hamilton142,143, Stephen W. Scherer144, 
Jeffrey Brandimarto17, Kenneth Margulies17, Christine E. Moravec17, Greco M. 
Fabiola Del47, Christian Fuchsberger145, Jeffrey R. O'Connell79,80, Wai K. Lee63, 
Graham C.M. Watt146, Harry Campbell147, Sarah H. Wild147, Nour E. El 
Mokhtari148, Norbert Frey149, Folkert W. Asselbergs150,151,152, Irene Mateo Leach8, 
Gerjan Navis153, Maarten P. van den Berg8, Dirk J. van Veldhuisen8, Manolis 
Kellis18,19, Bouwe P. Krijthe26,154, Oscar H. Franco26,154, Albert Hofman26,154, Jan 
A. Kors155, André G. Uitterlinden26,154,156, Jacqueline C.M. Witteman26,154, 
Lyudmyla Kedenko157, Claudia Lamina87, Ben A. Oostra26, Gonçalo R. 
Abecasis145, Edward G. Lakatta28, Antonella Mulas158, Marco Orrú158, David 
Schlessinger159, Manuela Uda158, Marcello R.P. Markus160, Uwe Völker30,161, 
Arking et al. Page 12
Nat Genet. Author manuscript; available in PMC 2015 February 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Harold Snieder38, Timothy D. Spector162, Johan Ärnlöv58,163, Lars Lind164, Johan 
Sundström164, Ann-Christine Syvänen58, Mika Kivimaki59, Mika Kähönen165, Nina 
Mononen46, Olli T. Raitakari166,167, Jorma S. Viikari168, Vera Adamkova70, Stefan 
Kiechl69, Maria Brion68,169, Andrew N. Nicolaides67,100, Bernhard Paulweber157, 
Johannes Haerting64, Anna F. Dominiczak63, Fredrik Nyberg130,170, Peter H. 
Whincup171, Aroon Hingorani59, Jean-Jacques Schott55,56, Connie R. Bezzina12, 
Erik Ingelsson58,172, Luigi Ferrucci52, Paolo Gasparini51,111, James F. Wilson147, 
Igor Rudan147, Andre Franke49, Thomas W. Mühleisen122,123,173, Peter P. 
Pramstaller47,174,175, Terho J. Lehtimäki46, Andrew D. Paterson176, Afshin 
Parsa79,80, Yongmei Liu177, Cornelia van Duijn26, David S. Siscovick13,94,97, 
Vilmundur Gudnason39,40, Yalda Jamshidi178, Veikko Salomaa115, Stephan B. 
Felix29,30, Serena Sanna158, Marylyn D. Ritchie179, Bruno H. 
Stricker26,154,155,156,180, Kari Stefansson24,40, Laurie A. Boyer20, Thomas P. 
Cappola17, Jesper V. Olsen22, Kasper Lage3,15,22,181,182, Peter J. Schwartz183, 
Stefan Kääb31,35, Aravinda Chakravarti1, Michael J. Ackerman53,54,184,*, Arne 
Pfeufer47,131,185,*, Paul I.W. de Bakker3,4,16,71,186,*, and Christopher Newton-
Cheh2,3,16,25,*
Affiliations
1Center for Complex Disease Genomics, McKusick-Nathans Institute of Genetic 
Medicine, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA 
2Center for Human Genetic Research, Massachusetts General Hospital, Boston, 
MA 02114, USA 3Program in Medical and Population Genetics, Broad Institute of 
Harvard and MIT, Cambridge, MA 02139, USA 4Department of Medical Genetics, 
University Medical Center Utrecht, Utrecht, The Netherlands 5Department of 
Molecular Medicine, Section of Cardiology, University of Pavia, Pavia, Italy 
6Department of Cardiology, Fondazione IRCCS Policlinico S. Matteo, Pavia, Italy 
7Institute of Human Genetics, Helmholtz Zentrum München, Neuherberg, Germany 
8Department of Cardiology, University of Groningen, University Medical Center 
Groningen, Groningen, The Netherlands 9Department of Genetics, University of 
Groningen, University Medical Center Groningen, 9700 RB Groningen, The 
Netherlands 10Clinical Pharmacology, William Harvey Research Institute, Barts and 
the London School of Medicine, Queen Mary University of London, London EC1M 
6BQ, UK 11Barts and the London Genome Centre, William Harvey Research 
Institute, Barts and the London School of Medicine, Queen Mary University of 
London, London EC1M 6BQ, UK 12Heart Failure Research Center, Department of 
Clinical and Experimental Cardiology, Academic Medical Center, Amsterdam, The 
Netherlands 13Cardiovascular Health Research Unit, Department of Medicine, 
University of Washington, Seattle, USA 14Cardiology Division, University of 
Washington, Seattle, WA, USA 15Analytic and Translational Genetics Unit, 
Massachusetts General Hospital, Boston, MA, 02114, USA 16Harvard Medical 
School, Boston, MA 02115, USA 17Perelman School of Medicine, University of 
Pennsylvania, Philadelphia PA, USA 18Broad Institute of MIT and Harvard, 
Cambridge, MA USA 19Computer Science and Artificial Intelligence Laboratory, 
Massachusetts Institute of Technology, Cambridge, MA 02139, USA 20Department 
Arking et al. Page 13
Nat Genet. Author manuscript; available in PMC 2015 February 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
of Biology, Massachusetts Institute of Technology, 77 Massachusetts Avenue, 
Cambridge, MA 02139 USA 21NHLBI's Framingham Heart Study, Framingham, MA, 
01702, USA 22Novo Nordisk Foundation Center for Protein Research, Faculty of 
Health Sciences, University of Copenhagen, Blegdamsvej 3b, Copenhagen, 
Denmark 23The Danish National Research Foundation Centre for Cardiac 
Arrhythmia, University of Copenhagen, Blegdamsvej 3b, DK-2200 Copenhagen, 
Denmark 24deCODE genetics, Sturlugata 8, 101 Reykjavik, Iceland 
25Cardiovascular Research Center, Massachusetts General Hospital, Boston, MA, 
USA 02114 26Department of Epidemiology, Erasmus Medical Center, P.O. Box 
2040, 3000 CA, Rotterdam, The Netherlands 27Center for Human Genetics 
Research, Vanderbilt University School of Medicine, Nashville, TN, 37232, USA 
28Laboratory of Cardiovascular Sciences, Human Cardiovascular Studies Unit, 
National Institute on Aging, National Institutes of Health, Baltimore, Maryland, 
21224 29Department of Internal Medicine B, University Medicine Greifswald, 17475 
Greifswald, Germany 30DZHK (German Center for Cardiovascular Research), 
partner site Greifswald, Germany 31Department of Medicine I, University Hospital 
Munich, Ludwig-Maximilians-University, Munich, Germany 32Institute of Medical 
Informatics, Biometry and Epidemiology, Chair of Epidemiology, Ludwig-
Maximilians-Universität, Munich, Germany 33Institute of Genetic Epidemiology, 
Helmholtz Zentrum Munich, German Research Center for Environmental Health, 
Neuherberg, Germany 34Institute of Medical Informatics, Biometry and 
Epidemiology, Chair of Genetic Epidemiology, Ludwig-Maximilians-Universität, 
Munich, Germany 35DZHK (German Centre for Cardiovascular Research), partner 
site Munich Heart Alliance, Munich, Germany 36Research Programs Unit, Molecular 
Medicine, University of Helsinki, 63FI-00014, Helsinki, Finland 37Department of 
Medicine, Helsinki University Central Hospital, FI-00029 HUS, Helsinki, Finland 
38Department of Epidemiology, University of Groningen, University MedicalCenter 
Groningen, Groningen, The Netherlands 39Icelandic Heart Association, Holtasmari 
1, IS-201 Kopavogur, Iceland 40Faculty of Medicine, University of Iceland, 101 
Reykjavik, Iceland 41Genetic Epidemiology Unit, Dept. of Epidemiology, Erasmus 
University Medical Center, 3000CA Rotterdam, the Netherlands 42California Pacific 
Medical Center Research Institute, San Francisco, CA 94107, USA 43Division of 
Cardiology, Johns Hopkins University School of Medicine, Baltimore, MD, 21205, 
USA 44Department of Epidemiology, Johns Hopkins University, Bloomberg School 
of Public Health, Baltimore, MD, 21205, USA 45Informatics and Biocomputing 
Platform, Ontario Institute for Cancer Research, Toronto, Canada, M5G 0A3 
46Department of Clinical Chemistry, Fimlab Laboratories and University of Tampere 
School of Medicine, P.O. Box 66, 33101 Tampere, Finland 47Center for 
Biomedicine, European Academy Bozen/Bolzano (EURAC), Bolzano, Italy - 
Affiliated Institute of the University of Lübeck, Lübeck, Germany 48Institute for 
Medical Informatics, Biometry and Epidemiology, University Hospital of Essen, 
University Duisburg-Essen, Essen, Germany 49Institute of Clinical Molecular 
Biology, Christian-Albrechts-University of Kiel, Schittenhelmstr. 12, 24105 Kiel, 
Germany 50MRC Human Genetics Unit, Institute of Genetics and Molecular 
Arking et al. Page 14
Nat Genet. Author manuscript; available in PMC 2015 February 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Medicine,Western General Hospital, Edinburgh, EH4 2XU, United Kingdom 
51Institute for Maternal and Child Health - IRCCS “Burlo Garofolo” – Trieste, Trieste, 
Italy, 34137 52Translational Gerontology Branch, National Institute on Aging, 
Baltimore, MD, 21225, USA 53Division of Pediatric Cardiology, Department of 
Pediatrics, Mayo Clinic, Rochester, MN, USA 55905 54Windland Smith Rice Sudden 
Death Genomics Laboratory, Department of Molecular Pharmacology & 
Experimental Therapeutics, Mayo Clinic, Rochester, MN, USA 55905 55l'institut du 
thorax, CHU de Nantes, Université de Nantes, Nantes, France, F-44000 56l'institut 
du thorax, INSERM UMR1087, CNRS UMR 6291, Université de Nantes, Nantes, 
France, F-44000 57Department of Medical Epidemiology and Biostatistics, 
Karolinska Institutet, Box 281, SE-171 77 Stockholm, Sweden 58Department of 
Medical Sciences, Molecular Epidemiology and Science for Life Laboratory, 
Uppsala University, Uppsala, Sweden 59Department of Epidemiology and Public 
Health, University College London, 1-19 Torrington Place, London, WC1E 6BT 
60University College London, Dept of Primary Care & Population Health, Royal Free 
Campus, London NW3 2PF, UK 61Department of Medical and Clinical Genetics, 
The Sahlgrenska Academy at the University of Gothenburg, 405 30 Gothenburg, 
Sweden 62The Biobanking and Molecular Resource Infrastructure of Sweden 
(BBMRI), Gothenburg, Sweden 63BHF Glasgow Cardiovascular Research Centre, 
Institute of Cardiovascular and Medical Sciences, College of Medical, Veterinary 
and Life Sciences, University of Glasgow, G12 8TA, UK 64Institute of Medical 
Epidemiology, Biostatistics, and Informatics, Martin-Luther-University Halle-
Wittenberg, 06112 Halle (Saale), Germany 65Second Department of Internal 
Medicine, Paracelsus Medical University/Salzburger Landeskliniken, 5020 Salzburg, 
Austria 66Cyprus International Institute for Environmental and Public Health in 
association with the Harvard School of Public Health, Cyprus University of 
Technology, Limassol, Cyprus 67Cyprus Cardiovascular and Educational Research 
trust, Nicosia, 2368, Cyprus 68Grupo de Medicina Xenómica, Centro Nacional de 
Genotipado-ISCIII, IDIS, Universidade de Santiago de Compostela 69Department of 
Neurology, Innsbruck Medical University, Anichstraβe 35, A-6020 Innsbruck, Austria 
70Centre for Experimental Medicine, Institute for Clinical and Experimental 
medicine, Videnska 1958/9, Prague 4, 14021, Czech Republic 71Division of 
Genetics, Department of Medicine, Brigham and Women's Hospital, Harvard 
Medical School, Boston, MA 02115, USA 72Harvard Bioinformatics and Integrative 
Genomics, Boston, Massachusetts, 02115 USA 73Partners HealthCare Center for 
Personalized Genetic Medicine, Boston, Massachusetts, USA 74Division of 
Rheumatology, Immunology, and Allergy, Brigham and Women's Hospital, Boston, 
Massachusetts, USA 75Faculty of Medical and Human Sciences, University of 
Manchester, Manchester, UK 76Computational and Systems Biology Program, 
Division of Biology and Biomedical Sciences, Washington University in St. Louis, St. 
Louis Missouri 77Division of Oncology, Department of Medicine, Washington 
University School of Medicine, St. Louis, Missouri 78Laboratory of Epidemiology, 
Demography and Biometry, National Institute on Aging, Bethesda, MD 20892, USA 
79Department of Medicine, University of Maryland School of Medicine, Baltimore, 
Arking et al. Page 15
Nat Genet. Author manuscript; available in PMC 2015 February 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Maryland, 21201, USA 80Program for Personalized and Genomic Medicine, 
University of Maryland, Baltimore, Maryland, 21201, USA 81Geriatric Research and 
Education Clinical Center, Veterans Administration Medical Center, Baltimore, 
Maryland, USA 82Division of Epidemiology and Community Health, School of Public 
Health, University of Minnesota, Minneapolis, Minnesota, United States of America 
83Department of Biomedical Engineering, Johns Hopkins University, Baltimore, MD 
21218, USA 84Electrocardiology, University of Glasgow Institute of Cardiovascular 
and Medical Sciences, Royal Infirmary, Glasgow G31 2ER 85Clinical Pharmacology, 
University of Cambridge, Addenbrooke's Hospital, Cambridge, UK 86Dept of 
Cardiovascular Science, University of Leicester, Glenfield Hospital, Groby Road, 
Leicester, LE3 9QP, UK 87Division of Genetic Epidemiology, Innsbruck Medical 
University, 6020 Innsbruck, Austria 88Full lists of members and affiliations appear in 
the Supplementary Note 89Department of Cardiology, Lund University, Lund, 
Sweden 90German Cancer Research Centre, Division of Cancer Epidemiology, 
69120 Heidelberg, Germany 91Department of Pharmacology, Ernst-Moritz-Arndt-
University of Greifswald, 17487 Greifswald, Germany 92Department of Medicine III, 
Medical Faculty, Martin-Luther-University Halle-Wittenberg, 06112 Halle (Saale), 
Germany 93Medical Genetics Unit, Casa Sollievo della Sofferenza, San Giovanni 
Rotondo, Italy 94Department of Epidemiology, University of Washington, Seattle, 
WA, USA 95Department of Health Services, University of Washington, Seattle, WA, 
USA 96Group Health Research Institute, Group Health Cooperative, Seattle, WA 
97Department of Medicine, University of Washington, Seattle, WA, USA 98Institute 
for Translational Genomics and Population Sciences, Los Angeles Biomedical 
Research Institute at Harbor-UCLA Medical Center, Torrance, CA, USA 
99Department of Public Health, Faculty of Medicine, University of Split, Soltanska 2, 
21000 Split, Croatia 100Vascular Screening and Diagnostic Centre, London, WB1 
7BZ, UK 101Division of Cardiology, Department of Medicine, Landspitali University 
Hospital, 101 Reykjavik, Iceland 102Department of Biomedical Informatics, 
Vanderbilt University School of Medicine, Nashville, TN, 37232, USA 103Department 
of Medicine, Vanderbilt University School of Medicine, Nashville, TN, 37232, USA 
104Department of Pharmacology, Vanderbilt University, Nashville, TN, 37232, USA 
105The Office of Personalized Medicine, Vanderbilt University, Nashville, TN, 37232, 
USA 106Sanofi Research & Development, Paris, France 107Department of 
Biostatistics, Boston University School of Public Health, Boston, MA, 02118, USA 
108Department of Mathematics and Statistics, Boston University, Boston, MA, 
02115, USA 109Cardiology Division, Massachusetts General Hospital, MA, 02114, 
USA 110Cardiovascular Department, Ospedali Riuniti and University of Trieste, 
Trieste, Italy, 34149 111University of Trieste, Trieste, Italy, 34137 112Fundación 
Publica Galega de Medicina Xenómica, SERGAS 113Center of Excellence in 
Genomic Medicine Research, King Abdulaziz University Jeddah, KSA 114Laboratory 
of Neurogenetics, National Institute on Aging, National Institutes of Health, 
Bethesda, MD, 20892, USA 115Chronic Disease Epidemiology and Prevention Unit, 
National Institute for Health and Welfare, PO Box 30, FI-00271 Helsinki, Finland 
116Department of Medicine, University of Helsinki, FI-00290 Helsinki, Finland 
Arking et al. Page 16
Nat Genet. Author manuscript; available in PMC 2015 February 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
117Division of Cardiology, Department of Medicine, Helsinki University Central 
Hospital, FI-00029 HUS, Helsinki, Finland 118Public Health Genomics Unit, National 
Institute for Health and Welfare, PO Box 30, FI-00271 Helsinki, Finland 119Institute 
for Molecular Medicine Finland FIMM, PO Box 20, FI-00014 University of Helsinki, 
Helsinki, Finland 120Estonian Genome Center, University of Tartu, Tartu, Estonia 
121Department of Cardiology, University Hospital of Essen, University Duisburg-
Essen, Essen, Germany 122Department of Genomics, Life & Brain Center, 
University of Bonn, Bonn, Germany 123Institute of Human Genetics, University of 
Bonn, Bonn, Germany 124Division of Medical Genetics, University Hospital Basel, 
Switzerland 125Department of Biomedicine, University of Basel, Switzerland 126MRC 
Epidemiology Unit, University of Cambridge, Institute of Metabolic Science, 
Addenbrooke's Hospital, Cambridge, UK 127The Mindich Child Health and 
Development Institute, The Icahn School of Medicine at Mount Sinai, New York, NY 
10069 128The Charles Bronfman Institute for Personalized Medicine, The Icahn 
School of Medicine at Mount Sinai, New York, NY 10069 129Department of 
Biostatistics, Institute of Basic Medical Sciences, University of Oslo, 0317 Oslo, 
Norway 130Department of Public Health and Community Medicine, Institute of 
Medicine, Sahlgrenska Academy, University of Gothenburg, 40530 Gothenburg, 
Sweden 131Institute of Human Genetics, Technische Universität München, Munich 
81675, Germany 132Research Unit of Molecular Epidemiology, Helmholtz Zentrum 
München, German Research Center for Environmental Health, Neuherberg, 
Germany 133Institute for Biological and Medical Imaging, Helmholtz Center Munich, 
German Research Center for Environmental Health, Neuherberg, Germany 
134Institute of Epidemiology II, Helmholtz Center Munich, German Research Center 
for Environmental Health, Neuherberg, Germany 135CK-CARE: Christine Kühne - 
Center for Allergy Research and Education 136Department of Dermatology and 
Allergy, Technische Universität München, Munich, Germany 137Department of 
Medicine, Hospital of Friedberg, Friedberg, Germany 138Department of Clinical 
Genetics, Academic Medical Center, Amsterdam, The Netherlands 139Princess Al-
Jawhara Al-Brahim Centre of Excellence in Research of Hereditary Disorders, 
Jeddah, Kingdom of Saudi Arabia 140Cardiovascular and Cell Sciences Institute, St 
George's University of London, London UK 141Biomedical Sciences, St Georges's 
University of London, Cranmer Terrace, London, SW17 0RE, UK 142The Labatt 
Family Heart CentreThe Hospital for Sick Children, Toronto, Ontario Canada M5G 
1X8 143Department of Pediatrics, The Hospital for Sick Children, Toronto, Ontario 
Canada M5G 1X8 144The Centre for Applied Genomics, The Hospital for Sick 
Children, Toronto, Ontario Canada M5G 1X8 145Center for Statistical Genetics, 
Department of Biostatistics, University of Michigan, Ann Arbor, MI, USA 146General 
Practice and Primary Care, University of Glasgow, 1 Horselethill Road, Glasgow 
G12 9LX, UK 147Centre for Population Health Sciences, University of Edinburgh, 
Teviot Place, Edinburgh, EH8 9AG, Edinburgh, Scotland 148Biobank PopGen, 
Institute of Experimental Medicine, Christian-Albrechts-University of Kiel, 24105 
Kiel, Germany 149Department of Internal Medicine III, University Medical Center 
Schleswig-Holstein, Campus Kiel, 24105 Kiel, Germany 150Durrer Center for 
Arking et al. Page 17
Nat Genet. Author manuscript; available in PMC 2015 February 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Cardiogenetic Research, ICIN-Netherlands Heart Institute, Utrecht, The 
Netherlands 151Department of Cardiology, Division Heart and Lungs, University 
Medical Centre Utrecht, Utrecht, The Netherlands 152Institute of Cardiovascular 
Science, faculty of Population Health Sciences, University College London, London, 
United Kingdom 153Department of Internal Medicine, University of Groningen, 
University Medical Center Groningen, Groningen, The Netherlands 154Netherlands 
Consortium for Healthy Aging (NCHA), The Netherlands 155Department of Medical 
Informatics, Erasmus Medical Center, P.O. Box 2040, 3000CA, Rotterdam, The 
Netherlands 156Department of Internal Medicine, Erasmus Medical Center, P.O. Box 
2040, 3000CA, Rotterdam, The Netherlands 157First Department of Internal 
Medicine, Paracelsus Medical University/Salzburger Landeskliniken, 5020 Salzburg, 
Austria 158Istituto di Ricerca Genetica e Biomedica, CNR, Monserrato, 09042 
Cagliari, Italy 159Laboratory of Genetics, Intramural Research Program, National 
Institute on Aging, National Institutes of Health, Baltimore, MD 21224, USA 
160Institute for Community Medicine, University Medicine Greifswald, 17487 
Greifswald, Germany 161Interfaculty Institute for Genetics and Functional Genomics, 
Ernst-Moritz-Arndt-University Greifswald, 17487 Greifswald, Germany 
162Department of Twin Research and Genetic Epidemiology, King's College 
London, London, United Kingdom 163School of Health and Social Sciences, Dalarna 
University Falun, Sweden 164Department of Medical Sciences, Uppsala University, 
Akademiska sjukhuset, SE-751 85 Uppsala, Sweden 165Department of Clinical 
Physiology, Tampere University Hospital and University of Tampere School of 
Medicine, P.O. Box 2000, Tampere 33521, Finland 166Department of Clinical 
Physiology and Nuclear Medicine, Turku University Hospital, P.O. Box 52, Turku 
20521, Finland 167Research Centre of Applied and Preventive Cardiovascular 
Medicine, University of Turku, P.O. Box 52, Turku 20521, Finland 168Department of 
Medicine, Turku University Hospital and University of Turku, P.O. Box 52, Turku 
20521, Finland 169Xenética de enfermidades cardiovasculares e oftalmolóxicas, 
IDIS. Complexo Hospitalario Universitario de Santiago-SERGAS. Red de 
Investigacion Cardiovascular 170Global Epidemiology, AstraZeneca R&D, 431 83 
Mölndal, Sweden 171Division of Population Health Sciences & Education, St 
George's University of London, London SW17 0RE, UK 172Wellcome Trust Centre 
for Human Genetics, University of Oxford, Oxford, OX3 7BN, United Kingdom 
173Institute of Neuroscience and Medicine (INM-1), Structural and Functional 
Organization of the Brain, Genomic Imaging, Research Centre Juelich, D-52425 
Juelich, Germany 174Department of Neurology, University of Lübeck, 23538 Lübeck, 
Germany 175Department of Neurology, General Central Hospital, 39100 Bolzano, 
Italy 176Genetics and Genome Biology Program,The Hospital for Sick Children 
Research Institute, Toronto, Ontario, M5G 1X8 , Canada 177Department of 
Epidemiology and Prevention, Division of Public Health Sciences, Wake Forest 
University, Medical Center Boulevard, Winston-Salem, NC 27157, USA 178Human 
Genetics Research Centre, St. George's University of London, London, SW17 0RE, 
United Kingdom 179Center for Systems Genomics, Pennsylvania State University, 
University Park, PA, 16802, USA 180Inspectorate of Health Care, P.O. BOX 16119, 
Arking et al. Page 18
Nat Genet. Author manuscript; available in PMC 2015 February 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
2500 BC , The Hague, The Netherlands 181Center for Biological Sequence Analysis, 
Department of Systems Biology, Technical University of Denmark, 2800 Lyngby, 
Denmark 182Pediatric Surgical Research Laboratories, MassGeneral Hospital for 
Children, Massachusetts General Hospital, 02114 Boston, MA, USA 183Center for 
Cardiac Arrhythmias of Genetic Origin, IRCCS Istituto Auxologico Italiano, Milan, 
Italy 184Division of Cardiovascular Diseases, Department of Medicine, Mayo Clinic, 
Rochester, MN, USA 55905 185Institute for Bioinformatics and Systems Biology, 
Helmholtz Zentrum München Germany 186Department of Epidemiology, University 
Medical Center Utrecht, Utrecht, The Netherlands
Acknowledgments
A full listing of acknowledgments is provided in the Supplementary Note.
References
1. Schwartz PJ, Crotti L, Insolia R. Long-QT syndrome: from genetics to management. Circ Arrhythm 
Electrophysiol. 2012; 5:868–77. [PubMed: 22895603] 
2. Newton-Cheh C, et al. QT interval is a heritable quantitative trait with evidence of linkage to 
chromosome 3 in a genome-wide linkage analysis: The Framingham Heart Study. Heart rhythm : 
the official journal of the Heart Rhythm Society. 2005; 2:277–84. [PubMed: 15851319] 
3. Newton-Cheh C, et al. Common variants at ten loci influence QT interval duration in the QTGEN 
Study. Nature genetics. 2009; 41:399–406. [PubMed: 19305408] 
4. Pfeufer A, et al. Common variants at ten loci modulate the QT interval duration in the QTSCD 
Study. Nat Genet. 2009; 41:407–14. [PubMed: 19305409] 
5. Arking DE, et al. A common genetic variant in the NOS1 regulator NOS1AP modulates cardiac 
repolarization. Nature genetics. 2006; 38:644–51. [PubMed: 16648850] 
6. Nolte IM, et al. Common genetic variation near the phospholamban gene is associated with cardiac 
repolarisation: meta-analysis of three genome-wide association studies. PloS one. 2009; 4:e6138. 
[PubMed: 19587794] 
7. Holm H, et al. Several common variants modulate heart rate, PR interval and QRS duration. Nat 
Genet. 2010; 42:117–22. [PubMed: 20062063] 
8. Noseworthy PA, et al. Common genetic variants, QT interval, and sudden cardiac death in a Finnish 
population-based study. Circulation. Cardiovascular genetics. 2011; 4:305–11. [PubMed: 
21511878] 
9. Kim JW, et al. A common variant in SLC8A1 is associated with the duration of the 
electrocardiographic QT interval. Am J Hum Genet. 2012; 91:180–4. [PubMed: 22726844] 
10. Yang J, et al. Genome partitioning of genetic variation for complex traits using common SNPs. Nat 
Genet. 2011; 43:519–25. [PubMed: 21552263] 
11. Voight BF, et al. The metabochip, a custom genotyping array for genetic studies of metabolic, 
cardiovascular, and anthropometric traits. PLoS Genet. 2012; 8:e1002793. [PubMed: 22876189] 
12. Smith JG, et al. Impact of Ancestry and Common Genetic Variants on QT Interval in African 
Americans. Circ Cardiovasc Genet. 2012; 5:647–655. [PubMed: 23166209] 
13. den Hoed M, et al. Identification of heart rate-associated loci and their effects on cardiac 
conduction and rhythm disorders. Nat Genet. 2013
14. Sotoodehnia N, et al. Common variants in 22 loci are associated with QRS duration and cardiac 
ventricular conduction. Nature genetics. 2010; 42:1068–76. [PubMed: 21076409] 
15. Pfeufer A, et al. Genome-wide association study of PR interval. Nature genetics. 2010; 42:153–9. 
[PubMed: 20062060] 
Arking et al. Page 19
Nat Genet. Author manuscript; available in PMC 2015 February 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
16. Elks CE, et al. Thirty new loci for age at menarche identified by a meta-analysis of genome-wide 
association studies. Nature genetics. 2010; 42:1077–85. [PubMed: 21102462] 
17. Zabaneh D, Balding DJ. A genome-wide association study of the metabolic syndrome in Indian 
Asian men. PloS one. 2010; 5:e11961. [PubMed: 20694148] 
18. Lemaitre RN, et al. Genetic loci associated with plasma phospholipid n-3 fatty acids: a meta-
analysis of genome-wide association studies from the CHARGE Consortium. PLoS genetics. 
2011; 7:e1002193. [PubMed: 21829377] 
19. Dupuis J, et al. New genetic loci implicated in fasting glucose homeostasis and their impact on 
type 2 diabetes risk. Nature genetics. 2010; 42:105–16. [PubMed: 20081858] 
20. Chambers JC, et al. Genome-wide association study identifies loci influencing concentrations of 
liver enzymes in plasma. Nature genetics. 2011; 43:1131–8. [PubMed: 22001757] 
21. Hu X, et al. Integrating autoimmune risk loci with gene-expression data identifies specific 
pathogenic immune cell subsets. Am J Hum Genet. 2011; 89:496–506. [PubMed: 21963258] 
22. Bernstein BE, et al. The NIH Roadmap Epigenomics Mapping Consortium. Nat Biotechnol. 2010; 
28:1045–8. [PubMed: 20944595] 
23. Ernst J, et al. Mapping and analysis of chromatin state dynamics in nine human cell types. Nature. 
2011; 473:43–9. [PubMed: 21441907] 
24. Corradin O, et al. Combinatorial effects of multiple enhancer variants in linkage disequilibrium 
dictate levels of gene expression to confer susceptibility to common traits. Genome Res. 2014; 
24:1–13. [PubMed: 24196873] 
25. Segre AV, et al. Common inherited variation in mitochondrial genes is not enriched for 
associations with type 2 diabetes or related glycemic traits. PLoS Genet. 2010; 6
26. Lage K, et al. A human phenome-interactome network of protein complexes implicated in genetic 
disorders. Nat Biotechnol. 2007; 25:309–16. [PubMed: 17344885] 
27. Rossin EJ, et al. Proteins encoded in genomic regions associated with immune-mediated disease 
physically interact and suggest underlying biology. PLoS genetics. 2011; 7:e1001273. [PubMed: 
21249183] 
28. Yoshida M, et al. Impaired Ca2+ store functions in skeletal and cardiac muscle cells from 
sarcalumenin-deficient mice. J Biol Chem. 2005; 280:3500–6. [PubMed: 15569689] 
29. Shimura M, et al. Sarcalumenin alleviates stress-induced cardiac dysfunction by improving Ca2+ 
handling of the sarcoplasmic reticulum. Cardiovasc Res. 2008; 77:362–70. [PubMed: 18006473] 
30. Jiao Q, et al. Sarcalumenin is essential for maintaining cardiac function during endurance exercise 
training. Am J Physiol Heart Circ Physiol. 2009; 297:H576–82. [PubMed: 19502553] 
31. Splawski I, et al. Severe arrhythmia disorder caused by cardiac L-type calcium channel mutations. 
Proceedings of the National Academy of Sciences of the United States of America. 2005; 
102:8089–96. discussion 8086-8. [PubMed: 15863612] 
32. Milberg P, et al. Inhibition of the Na+/Ca2+ exchanger suppresses torsades de pointes in an intact 
heart model of long QT syndrome-2 and long QT syndrome-3. Heart rhythm : the official journal 
of the Heart Rhythm Society. 2008; 5:1444–52. [PubMed: 18929333] 
33. Milberg P, et al. Acute inhibition of the Na(+)/Ca(2+) exchanger reduces proarrhythmia in an 
experimental model of chronic heart failure. Heart rhythm : the official journal of the Heart 
Rhythm Society. 2012; 9:570–8. [PubMed: 22075452] 
34. Pott C, et al. Proarrhythmia in a non-failing murine model of cardiac-specific Na(+)/Ca (2+) 
exchanger overexpression: whole heart and cellular mechanisms. Basic research in cardiology. 
2012; 107:1–13.
35. Braz JC, et al. PKC-alpha regulates cardiac contractility and propensity toward heart failure. Nat 
Med. 2004; 10:248–54. [PubMed: 14966518] 
36. Sakuntabhai A, et al. Mutations in ATP2A2, encoding a Ca2+ pump, cause Darier disease. Nature 
genetics. 1999; 21:271–7. [PubMed: 10080178] 
37. Ji Y, et al. Disruption of a single copy of the SERCA2 gene results in altered Ca2+ homeostasis 
and cardiomyocyte function. J Biol Chem. 2000; 275:38073–80. [PubMed: 10970890] 
Arking et al. Page 20
Nat Genet. Author manuscript; available in PMC 2015 February 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
38. Pani B, et al. Up-regulation of transient receptor potential canonical 1 (TRPC1) following 
sarco(endo) plasmic reticulum Ca2+ ATPase 2 gene silencing promotes cell survival: a potential 
role for TRPC1 in Darier's disease. Mol Biol Cell. 2006; 17:4446–58. [PubMed: 16899508] 
39. Lyon AR, et al. SERCA2a gene transfer decreases sarcoplasmic reticulum calcium leak and 
reduces ventricular arrhythmias in a model of chronic heart failure. Circulation. Arrhythmia and 
electrophysiology. 2011; 4:362–72. [PubMed: 21406682] 
40. Jin J, et al. Deletion of Trpm7 disrupts embryonic development and thymopoiesis without altering 
Mg2+ homeostasis. Science. 2008; 322:756–60. [PubMed: 18974357] 
41. Runnels LW, Yue L, Clapham DE. TRP-PLIK, a bifunctional protein with kinase and ion channel 
activities. Science. 2001; 291:1043–7. [PubMed: 11161216] 
42. Elizondo MR, et al. Defective skeletogenesis with kidney stone formation in dwarf zebrafish 
mutant for trpm7. Curr Biol. 2005; 15:667–71. [PubMed: 15823540] 
43. Arduini BL, Henion PD. Melanophore sublineage-specific requirement for zebrafish touchtone 
during neural crest development. Mech Dev. 2004; 121:1353–64. [PubMed: 15454265] 
44. Sah R, et al. Ion channel-kinase TRPM7 is required for maintaining cardiac automaticity. Proc Natl 
Acad Sci U S A. 2013; 110:E3037–46. [PubMed: 23878236] 
45. Wei C, et al. Calcium flickers steer cell migration. Nature. 2009; 457:901–5. [PubMed: 19118385] 
46. Du J, et al. TRPM7-mediated Ca2+ signals confer fibrogenesis in human atrial fibrillation. Circ 
Res. 2010; 106:992–1003. [PubMed: 20075334] 
47. Sah R, et al. Timing of myocardial trpm7 deletion during cardiogenesis variably disrupts adult 
ventricular function, conduction, and repolarization. Circulation. 2013; 128:101–14. [PubMed: 
23734001] 
48. Willer CJ, Li Y, Abecasis GR. METAL: fast and efficient meta-analysis of genomewide 
association scans. Bioinformatics. 2010; 26:2190–1. [PubMed: 20616382] 
49. Pe'er I, Yelensky R, Altshuler D, Daly MJ. Estimation of the multiple testing burden for 
genomewide association studies of nearly all common variants. Genet Epidemiol. 2008; 32:381–5. 
[PubMed: 18348202] 
50. Ernst J, Kellis M. Discovery and characterization of chromatin states for systematic annotation of 
the human genome. Nat Biotechnol. 2010; 28:817–25. [PubMed: 20657582] 
51. Schwartz PJ, Moss AJ, Vincent GM, Crampton RS. Diagnostic criteria for the long QT syndrome. 
An update. Circulation. 1993; 88:782–4. [PubMed: 8339437] 
Author contributions
Author contributions are indicated by cohort/group. All co-authors revised and approved the 
manuscript.
Writing Group. C.N.-C. takes overall responsibility for the QT-IGC study. The study 
design was developed by M.J.A., D.E.A., A.C., L.C., P.I.W.d.B., T.T.K., P.B.M., C.N.-C., 
A.P., S.L.P., P.J.S., N.S. in consultation with the respective study groups. The manuscript 
was written by C.N.-C. The manuscript was critically revised in detail by members of the 
writing team before circulation to all co-authors.
GWAS cohorts. AGES: Phenotyping: V.G. Data analysis: A.V.S. Oversight: T.B.H., 
L.J.L., V.G. Amish studies: Clinical data collection, genotyping and oversight: B.D.M., 
A.R.S. EKG data collection: W.P. Analysis: A.Parsa, J.R.O. Interpretation: A.Parsa, W.S.P. 
ARIC: Study design: A.A., D.E.A, A.C., W.H.L.K. Analyses: D.E.A., J.S.B., A.C., G.E., 
H.H. Steering: D.E.A, A.C. Writing: D.E.A., A.C. BLSA: Analysis: T.T. Phenotype 
collection: J.B.S. Overall project supervision: L.F. BRIGHT: Phenotyping: M.B., M.J.C., 
P.W.M., P.B.M., N.J.S. Genotyping: P.B.M., S.J.N. Analysis: S.J.N. Overall study 
supervision: M.B., M.J.C., P.B.M., N.J.S. Carlantino: Sample/data collection: M.C., L.Z. 
Arking et al. Page 21
Nat Genet. Author manuscript; available in PMC 2015 February 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Overall study supervision: P.G.. Data collection/statistical analysis: S.U. CHS: Study 
design: J.B., S.R.H., B.P., N.S. Data collection: S.R.H., B.P., D.S.S. Genotyping: J.I.R. 
Analysis, interpretation: J.B., N.S. Supervision of analyses: B.P. Funding for GWAS: B.P. 
Croatia-Korcula& Croatia-Split: GWAS analysis: C.H. Data collection, phenotype 
measurement, data entry, and field work supervision: I.K., O.P. Study design, funding: I.R., 
A.F.W. DCCT/EDIC: Analyses: D.W. Supervision of analyses: A.D.P. deCODE: Data 
collection: D.O.A., H.H. Study design: K.S., U.T., H.H., D.F.G., D.O.A. Data alignment, 
imputation and statistical analysis: D.F.G. Additional analysis, interpretation of results: K.S., 
U.T., H.H., D.F.G., D.O.A. eMERGE: Data curation, GWAS analysis: R.L.Z., Y.B. 
Supervision of QC/analysis of dataset: M.D.R. Study conception, analysis framework: D.R. 
Algorithm for case ascertainment: J.C.D. ERF: Analysis: A.I. Data acquisition: C.v.D., A.I., 
B.A.O., J.A.K., A.G.U. Overall study PIs: C.v.D., B.A.O. FHS: Analysis plan development: 
C.N.-C., C.O.D., P.A.N., M.G.L. GWAS analysis: X.Y.Y., M.G.L. Wrote manuscript: C.N.-
C. Secured funding: C.N.-C., C.J.O. FVG: Data collection: M.B. Primary analysis: A.I. 
Statistical analysis: A.P.d'A. Overall study supervision: G.S. Health2000: Data analysis, 
replication genotyping, QC: A.M.L. Primary data analysis: A.Marjamaa. Phenotyping, 
including ECGs: A.J. Electrocardiographic measurements: K.P. GWAS and replication 
genotyping: M.P. Design of ECG study, analysis, interpretation: L.O. Genetic data 
collection, analysis: K.K.K. PI, supervision: V.S. HealthABC: Data collection, supervision: 
S.R.C., Y.L. Data analysis: D.S.E., M.A.N. HNR: Data collection: H.K. Data generation: 
H.K., T.W.M. Genetic data generation: M.N.N., P.H., T.W.M. Data analysis: L.E., P.H., 
T.W.M., M.N.N. Overall study design, PIs: R.E., K.-H.J. KORA-F3/S4: Overall QT project 
supervision: A.Pfeufer. Genotyping oversight: T.M. ECG collection, measurement and 
interpretation: M.F.S., S.P., B-M.B, E.M. Primary genetic analysis: M.M.-N. Interpretation 
of results: A.Pfeufer, S.Kaab, T.M., M.W. Overall study PI: A.Peters. LifeLines: 
Phenotyping: R.A.d.B., P.A.v.d.V. Genotyping: L.F. Analyses: I.M.N. and L.F. MICROS: 
Sample recruitment, overall study PI: P.P. Study supervision, genotyping, data coordination: 
A.A.H. Data analysis: F.D.G., C.F. ORCADES: Phenotype collection: S.H.W. Genotype 
generation: H.C., J.F.W. GWAS analysis: P.N. Raised funding: J.F.W. Overall study 
supervision: J.F.W. PopGen: Recruitment, phenotyping: N.E.E.M., N.F. Genotyping, data 
preparation: A.F. Data preparation, analysis: D.E. PREVEND: Phenotyping: M.P.v.d.B., 
D.J.v.V, G.N. Genotyping, data-analysis: F.W.A., I.M.L., P.v.d.H. Obtained funding: G.N., 
D.J.v.V., F.W.A., P.v.d.H. Rotterdam Study-I and II: Study concept, design: M.E., 
B.H.C.S. Data acquisition: M.E., B.P.K., J.A.K., A.H., J.C.M.W., B.H.C.S., A.G.U. 
Statistical analysis: M.E. Interpretation: M.E., B.H.C.S. Obtained funding: A.H., J.C.M.W., 
A.G.U., B.H.C.S. Study supervision: B.H.C.S. SardiNIA: Phenotyping: M.O. Genotyping, 
data analysis: G.A., E.G.L., A.Mulas, M.O., S.S., D.S., K.V.T., and M.U. Overall study 
supervision, PIs: D.S., M.U. SHIP: Data acquisition: M.D., M.R.P.M., U.V., S.B.F. 
Statistical analysis: U.V., M.D., M.R.P.M. Interpretation: U.V., M.D., S.B.F. 
Obtained funding: S.B.F., U.V. TwinsUK: Study concept, design: H.S., Y.J. Data 
acquisition: T.D.S. Statistical analysis, interpretation: I.M.N., H.S., Y.J. Obtained funding: 
Y.J., T.D.S. Young Finns Study: Data collection: T.L., O.R., M.Kähönen, J.V. Genotyping: 
T.L., N.M. Genotyping: T.L. Phenotype preparation: O.R., M.Kähönen, J.V. Analysis: T.L., 
O.R., M.Kähönen, J.V., L.-P.-L. Obtained funding: T.L., O.R., M.Kähönen, J.V.
Arking et al. Page 22
Nat Genet. Author manuscript; available in PMC 2015 February 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Directly genotyped SNP replication cohorts. (Author contributions for cohorts that 
contributed to both GWAS and replication genotyping are shown under the GWAS entry 
above) BRHS: Analysis: R.W.M. Custodian of genetic resource: R.W.M., P.H.W. Data 
collection for genetic resource: P.H.W. Development of genetic resource: A.D.H. Overall 
study supervision, PIs: P.H.W., R.W.M. ECG analyses: P.W.M. Bruneck: Data analysis, 
interpretation, writing: S.K. DNA preparation: F.K., C.L. ECG measurement, database: 
M.Knoflauch. Supervision, funding, administration, PI: J.W. Carla: Study concept, design: 
K.H.G., K.W. Genotyping: H.M.z.S. Supervision: K.W. Study design, analysis: A.K. Study 
concept, supervision, PI: J.H. Cyprus: Study concept, funding, supervision, analysis: A.N. 
Data acquisition, analysis, interpretation: M.G. Genetic, biochemical data acquisition, 
statistical analysis: A.G.P. Czech Post-MONICA: Data collection, submission: J.A.H., 
V.A. Galicia: Cohort collection: M.B. Study design: M.B. Genotyping platform 
management: A.C. Genotyping: M.T. Analysis: M.T. Interpretation: M.B., A.C. Financial 
support: A.C. Intergene: Genotyping, data analysis, epidemiology expertise: F.N. 
Genotyping, genetic expertise: A.T.N. Study design, data collection, disease area 
knowledge: D.S.T. MIDSPAN Family Study: Data acquisition, statistical analysis, 
interpretation: S.P. Genotyping: W.K.L. Overall study supervision, data collection, funding: 
A.F.D., G.C.M.W. PIVUS: Genotyping: A.-C.S. Phenotyping: L.L., J.A., J.S. Data analysis: 
S.G. Overall supervision, PI: E.I. SAPHIR: DNA preparation: F.K., C.L. Data collection: 
L.K., B.P., B.S. Data analysis: L.K., F.K., C.L., B.P., B.S. Study design, PI: B.P. ULSAM: 
Genotyping: A.-C.S. Phenotyping: L.L., J.A., J.S. Data analysis: S.G. Overall supervision, 
PI: E.I. Whitehall II: Data collection, submission: M.Kumari. Overall supervision: 
M.Kivimaki. Funding: A.H.
Meta-analysis of GWAS + replication. D.E.A. and S.L.P. independently performed quality 
control and meta-analysis of GWAS and replication association results. P.I.W.d.B., A.P. and 
C.N.-C. supervised the analyses.
Non-QT trait lookups. CARe-COGENT: Meta-analysis, lookup: J.G.S. HRGEN: Meta-
analysis, lookup: M.d.H. Overall study supervision: R.J.F.L. QRS GWAS: Study 
supervision: N.S. Meta-analysis: D.E.A., P.I.W.d.B. Results lookup: S.L.P.
eQTL Analyses. Dataset acquisition: A.S.P., V.E. Analysis, interpretation: A.D.J. Cell-type 
enrichment tests: S.R.
Left ventricle eSNP analyses. Overall supervision: T.P.C. Recruitment, sample collection: 
K.M., C.M. Sample processing, expression analysis: J.B. Statistical analysis: M.M.
Left ventricle enhancer analyses. Analysis: X.W. Overall supervision: L.A.B., M.Kellis
Mouse knockout. Enrichment tests: K.S.
DAPPLE analysis. Concept, design, analysis: E.J.R. conceived, designed and performed the 
DAPPLE analyses. Supervision: K.L., M.J.D.
LQTS mutation screening. Amsterdam: SLC8A1 Sequencing: T.K.T. Clinical data 
collection: A.B., N.H., A.A.M.W. Study supervision: C.R.B., A.A.M.W. London: 
Arking et al. Page 23
Nat Genet. Author manuscript; available in PMC 2015 February 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Recruitment, phenotyping, strategy: E.R.B. Screening for mutations in LQT1,2,3 and sample 
management: C.D. Mayo: LQTS cohort characteristic organization: D.J.T. TRPM7 mutation 
analysis, interpretation: D.J.T., A.M.D., J.R.G. Patient collection, study design, data review, 
overall supervision: M.J.A. Munich: Study oversight: S.Kääb, A.Pfeufer. Patient collection: 
B.M.B., E.M. Nantes: Scientific management: J-J.S Clinical, genetic information collection: 
S.C. ATP2A2 sequencing: S.C. Screening for mutations in LQT1,2,3, and clinical data 
collection: J.B. LQTS gene diagnosis management: F.K. Patient enrollment: V.P. Pavia: 
Patient collection, patient selection, molecular screening supervision: L.C., P.J.S. SRL 
mutation screening: A.G., R.I. Toronto: Identification of LQTS patients free of LQT1,2,3 
mutations: R.M.H. Program co-development: S.W.S.
Immunoprecipitation experiments. Proteomic experiments, analysis:A.L. Overall study 
supervision: J.V.O.
Arking et al. Page 24
Nat Genet. Author manuscript; available in PMC 2015 February 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Figure 1. 
Genome-wide association results for GWAS meta, annotated with gene names. Shown are 
association results from meta-analysis of QT interval GWAS in 76,198 individuals of 
European ancestry across 22 autosomes. Loci meeting P < 5×10-8 upon meta-analysis with 
replication data are annotated for novel (large font) and previously reported (small font) loci. 
Nearest genes are used for annotation but the causal gene at any given locus is unknown.
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